Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06379399
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2024-04-18
Brief Title:
TrifluridineTipiracil Combined With Cetuximab in the Treatment of Third-line and Above RASBRAF Wild-type mCRC
Sponsor:
Wangxia LV
Organization:
Zhejiang Cancer Hospital
Study Overview
Official Title:
TrifluridineTipiracil Combined With Cetuximab in the Treatment of Third-line and Above RASBRAF Wild-type Metastatic Colorectal Cancer A Single-center Prospective Phase IbII Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-center prospective single-arm exploratory study aimed at evaluating the efficacy and safety of trifluridinetipiracil in combination with cetuximab in the treatment of third-line and above RASBRAF wild-type metastatic colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None